drugset / Trial / NCT00796601

Maintenance of Efficacy.

NCT00796601

Phase 3 Withdrawn Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The hypothesis of Study A6061054 is to demonstrate superiority of efficacy of esreboxetine at 3 and 6 months compared to placebo.

Timeline

Start
2009-05-01
Primary completion
2010-05-01
Completion
2010-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject [S,S]-Reboxetine Unknown 2 mg
Subject [S,S]-Reboxetine Unknown 6 mg
Subject [S,S]-Reboxetine Unknown 8 mg
Subject [S,S]-Reboxetine Unknown 10 mg

Indications